Research
    Yun Jingping
    Title Director of Pathology Department and Professor
    Profile

    Dr. Jingping Yun is currently a Professor of Pathology at Sun Yat-sen University Cancer Center. He served as the Director of Pathology Department in SYSUCC since 2010. He specializes in the pathological diagnosis of tumor for nearly 30 years. Dr. Yun had been further educated in Prince of Wales Hospital in 1997. He currently serves as Vice Chairman in the pathologists committee of CSCO and the Pathology Branch of Guangdong Medical Doctor Association. He is also the chairman-elected of the pathologists committee of Guangdong Anti-cancer Association. Dr. Yun is known for his academic contributions to molecular mechanism in liver cancer development, as well as the  prognostic, predictive, and diagnostic markers for GI tumors. He has authored or co-authored over 90 peer-reviewed articles, including some papers in renowned journals, such as Hepatology, Cancer research, Oncogene, Cancer letters, etc. and undertaken over 20 national scientific research programs. Dr. Yun also authored book chapters, abstracts and exhibits, and given lectures worldwide. In 2018, he was awarded the leading medical talents of Guangdong Province. In 2019, he was honored with the second prize of National Scientific and Technological Progress Award and Wiley Health Science Researcher Award.

    Email yunjp@sysucc.org.cn
    Phone +86 20 87343693
    Research Interest(s)

    Molecular mechanism in liver cancer development. Prognostic, predictive, and diagnostic markers for GI tumors

    For information on Professor Yun's laboratory, click here and select: Mechanisms involved in hepatocarcinogenesis and tumor metastasis.

    Education

    MD., Hunan Medical University, China, 1980-1985.

    MA. in Pathology, Sun Yat-Sen University, China, 1988-1991.

    Ph.D in Pathology, The Chinese University of Hong Kong, China, 1998-2001.

    Publications

    1. Chen SL, Liu LL, Wang CH, Lu SX, Yang X, He YF, Zhang CZ, Yun JP*. Loss of RDM1 enhances hepatocellular carcinoma progression via p53 and Ras/Raf/ERK pathways. Mol Oncol 2019 Oct 31.

    2. Huang YH, Yan SM, Liu LL, Lu JB, Yang X, He YF, Yun JP*. Incidental lymphoma in lymph node dissection for carcinoma in the abdominopelvic cavity: a single-institution experience. Virchows Arch. 2019 Sep; 475(3).

    3. Huang YH,Shi XL, Zhong P,Wang Y, Xiao HL, Zhou XG, Yun JP*. De Novo Testicular Extranodal NK/T-Cell Lymphoma A Clinicopathologic Study of 21 Cases With Review of Additional 18 Cases in the Literature. Virchows Arch.2019 Sep;475(3):365-372

    4. Chen SL, Zhang CZ, Liu LL, Lu SX, Pan YH, Wang CH, He YF, Lin CS, Yang X, Xie D, Yun JP*. A GYS2/p53 Negative Feedback Loop Restricts Tumor Growth in HBV-Related Hepatocellular Carcinoma. Cancer Res. 2019 02 01;79(3).

    5. Wang H, Zhang CZ, Lu SX, Zhang MF, Liu LL, Luo RZ, Yang X, Wang CH, Chen SL, He YF, Xie D, Xu RH, Yun JP*. A Coiled-Coil Domain Containing 50 Splice Variant Is Modulated by Serine/Arginine-Rich Splicing Factor 3 and Promotes Hepatocellular Carcinoma in Mice by the Ras Signaling Pathway. Hepatology 2019 Jan; 69(1).

    6. Zhang CZ, Chen SL,Wang CH,,He YF,Yang X, Xie D, Yun JP*. CBX8 exhibits oncogenic activity via AKT/β-Catenin activation in hepatocellularcarcinoma. Cancer Res. 2018 Jan 1; 78(1):51-63.

    7. Chen SL, Liu LL, Lu SX, Luo RZ, Wang CH, Wang H, Cai SH, Yang X, Xie D, Zhang CZ, Yun JP*. HBx-mediated decrease of AIM2 contributes to hepatocellular carcinoma metastasis. Mol Oncol. 2017 Sep; 11(9):1225-1240.

    8. Chen SL, Liu LL, Lu SX, Luo RZ, Wang CH, Wang H, Cai SH, Yang X, Xie D, Zhang CZ, Yun JP*. HBx-mediated decrease of AIM2 contributes to hepatocellular carcinoma metastasis. Mol Oncol. 2017 Sep; 11(9):1225-1240.

    9. Lu SX, Zhang CZ, Luo RZ, Wang CH, Liu LL, Fu J, Zhang L, Wang H, Xie D, Yun JP*. Zic2 promotes tumor growth and metastasis via PAK4 in hepatocellular carcinoma. Cancer Lett. 2017 Aug 28; 402:71-80.

    10. Zhou X, Zhang CZ, Lu SX, Chen GG, Li LZ, Liu LL, Yi C, Fu J, Hu W, Wen JM, Yun JP*. miR-625 suppresses tumour migration and invasion by targeting IGF2BP1 in hepatocellular carcinoma. Oncogene. 2015 Feb 19; 34(8):965-77.

    11. Yi C, Wang Q, Wang L, Huang Y, Li L, Liu L, Zhou X, Xie G, Kang T, Wang H, Zeng M, Ma J, Zeng Y, Yun JP*. MiR-663, a microRNA targeting p21 (WAF1/CIP1), promotes the proliferation and tumorigenesis of nasopharyngeal carcinoma. Oncogene 2012; 31:4421-33.

    12. Wang CH, Li M, Liu LL, Zhou RY, Fu J, Zhang CZ*, Yun JP*.  LRG1 expression indicates unfavorable clinical outcome in hepatocellular carcinoma. Oncotarget. 2015 Dec 8; 6(39):42118-29.

    13. Hu W, Lu SX, Li M, Zhang C, Liu LL, Fu J, Jin JT, Luo RZ, Zhang CZ*, Yun JP*. Pyruvate kinase M2 prevents apoptosis via modulating Bim stability and associates with poor outcome in hepatocellular carcinoma. Oncotarget. 2015 Mar 30;6(9):6570-83.

    14. Liu LL, Lu SX, Li M, Li LZ, Fu J, Hu W, Yang YZ, Luo RZ, Zhang CZ*, Yun JP*. FoxD3-regulated microRNA-137 suppresses tumour growth and metastasis in human hepatocellular carcinoma by targeting AKT2. Oncotarget 2014 Jul 15;5(13):5113-24.

    15. Li LZ, Zhang CZ, Liu LL, Yi C, Lu SX, Zhou X, Zhang ZJ, Peng YH, Yang YZ, Yun JP*. miR-720 inhibits tumor invasion and migration in breast cancer by targeting TWIST1. Carcinogenesis 2014;35:469-78.

    16. Hu W,Fu J,Lu SX,Liu LL,Luo RZ,Yun JP*,Zhang CZ*. Decrease of Bcl-xL/Bcl-2-associated death promoter in hepatocellular carcinoma indicates poor prognosis. Am J Cancer Res.  2015 Apr 15;5(5):1805-13.

    17. Zhang CZ, Fang EF, Zhang HT, Liu LL, Yun JP*. Momordica charantia lectin exhibits antitumor activity towards hepatocellular carcinoma. Invest New Drugs. 2015 Feb;33(1):1-11.

    18. Fu J, Li M, Wu DC, Liu LL, Chen SL, Yun JP. Increased Expression of CAP2 Indicates Poor Prognosis in Hepatocellular Carcinoma. Transl Oncol. 2015 Oct;8(5):400-6.

    19. Liu LL, Zhang MF, Pan YH, Yun JP*, Zhang CZ*. NORE1A sensitises cancer cells to sorafenib-induced apoptosis and indicates hepatocellular carcinoma prognosis. Tumour Biol 2014.

    20. Fu J, Qiu H, Cai M, Pan Y, Cao Y, Liu L, Yun JP*, Zhang CZ*. Low cyclin F expression in hepatocellular carcinoma associates with poor differentiation and unfavorable prognosis. Cancer Sci 2013;104:508-15.

    21. Luo R, Zhang M, Liu L, Lu S, Zhang CZ*, Yun JP*. Decrease of fibulin-3 in hepatocellular carcinoma indicates poor prognosis. PLoS One 2013;8:e70511.

    22. Huang Y, Li LZ, Zhang CZ, Yi C, Liu LL, Zhou X, Xie GB, Cai MY, Li Y, Yun JP*. Decreased expression of zinc-alpha2-glycoprotein in hepatocellular carcinoma associates with poor prognosis. J Transl Med 2012;10:106.

    23. Cai MY, Luo RZ, Chen JW, Pei XQ, Lu JB, Hou JH, Yun JP*. Overexpression of ZEB2 in peritumoral liver tissue correlates with favorable survival after curative resection of hepatocellular carcinoma. PLoS One 2012;7:e32838.

    24. Wang X, Liang Y, Chen Q, Xu HM, Ge N, Luo RZ, Shao JY, He Z, Zeng YX, Kang T, Yun JP*, Xie F*. Prognostic significance of SOX2 expression in nasopharyngeal carcinoma. Cancer Invest 2012;30:79-85.

    25. Zhang CZ, Liu L, Cai M, Pan Y, Fu J, Cao Y, Yun JP*. Low SIRT3 expression correlates with poor differentiation and unfavorable prognosis in primary hepatocellular carcinoma. PLoS One 2012;7:e51703.

    26. Liu L, Zhang CZ, Cai M, Fu J, Chen GG, Yun JP*. Downregulation of polo-like kinase 4 in hepatocellular carcinoma associates with poor prognosis. PLoS One 2012;7:e41293.

    27. Zhang CZ, Pan Y, Cao Y, Lai PB, Liu L, Chen GG, Yun JP*. Histone deacetylase inhibitors facilitate dihydroartemisinin-induced apoptosis in liver cancer in vitro and in vivo. PLoS One 2012;7:e39870.

    28. Li JD, Zhuang Y, Li YF, Feng YL, Hou JH, Chen L, Zhu AN, Wu QL, Yun JP*. A clinicopathological aspect of primary small-cell carcinoma of the uterine cervix: a single-centre study of 25 cases. J Clin Pathol 2011;64:1102-7.

    29. He L, Ding H, Wang JH, Zhou Y, Li L, Yu YH, Huang L, Jia WH, Zeng M, Yun JP, Luo RZ, Zheng M. Overexpression of karyopherin 2 in human ovarian malignant germ cell tumor correlates with poor prognosis. PLoS One 2012;7:e42992.

    30. Huang L, Zheng M, Zhou QM, Zhang MY, Jia WH, Yun JP*, Wang HY. Identification of a gene-expression signature for predicting lymph node metastasis in patients with early stage cervical carcinoma. Cancer 2011;117:3363-73.

    31. Wang QQ, Zhang ZY, Xiao JY, Yi C, Li LZ, Huang Y, Yun JP*. Knockdown of nucleophosmin induces S-phase arrest in HepG2 cells. Chin J Cancer 2011;30:853-60.

    32. Lv L, Pan K, Li XD, She KL, Zhao JJ, Wang W, Chen JG, Chen YB, Yun JP*, Xia JC. The accumulation and prognosis value of tumor infiltrating IL-17 producing cells in esophageal squamous cell carcinoma. PLoS One 2011; 6: e18219.

    Updated May 2020

    Zhang Huizhong
    Title Deputy Director of Department of Pathology, Associate professor and Advisor of master’s degree student
    Profile

    Born in 1962, Prof. Zhang Huizhong was admitted to Clinical Department of former Zhongshan Medical School in 1980, graduated in 1986 and was conferred upon a bachelor's degree in medicine. In the same year he was admitted to former Zhongshan Medical School to pursue a master's degree in medicine. After graduation, he stayed at Department of Pathology in former Zhongshan Medical School, engaging himself in the diagnosis, research and teaching of tumor pathology. He was admitted to former Sun Yat-sen University of Medical Sciences in 1995, studying pathology, and graduated with a doctoral degree in medicine in 1999. He has engaged in the diagnosis, research and teaching of tumor pathology for over a decade. The number of pathology and cytology diagnostic cases and difficult case consultations in a year is about 7,000. He has accumulated rich experiences in histopathology and pathology and cytology cancer diagnostics.

    Now he is the Deputy Director of Department of Pathology, an associate professor and a associate chief physician, specializes in the diagnosis and research of bone tissue tumors and liver tumors. He has undertaken and completed a number of research projects and published multiple papers.

    Email zhanghuizh@sysucc.org.cn
    Phone
    Research Interest(s)

    1. Collagen gene expression of Osteoblastic tumor and its relation with taxonomic differentiation and prognosis.

    2. Experimental study on HRG-PE recombinant toxin-oriented biological gene for breast cancer treatment.

    3. Clinical and laboratory studies of operative indications of selective neck dissection for head and neck cancers.

    4. Nm23 and P21 protein expression in three kinds of skin tumors with different metastatic potential.

    5. Immunohistochemistry used to detect hepatitis G virus in liver tissue of a liver cancer patient.

    6. Molecular mechanism of the expression of Osteosarcoma type I collagen.

    7. In situ telomerase activity detection in benign and malignant epithelial tissue of colons and its clinical significance.

    Education
    Publications
    Xie Dan
    Title Deputy Director and Professor
    Profile

    Dr Xie is a Professor and Vice Director of the Department of Pathology, Sun Yat-Sen University Cancer Center. He is a Principle Investigator of the State Key laboratory of Oncology in South China, and the Vice Chairman of Young committee members in Cancer Metastasis Association of Chinese Anticancer Association. He is one of the Distinguished Young Scholars (National Nature Science Fund of China) and Outstanding Scholars in New Era (the Ministry of Education of China). Dr Xie’s research focuses on the genetic mechanisms and/or prediction biomarkers of cancer metastasis in several types of human carcinomas including colorectal, hepatoceullar, oesophageal and lung cancers. 

    He has been granted by National Fund for Outstanding Young Scientists of China, the National Basic Research Program (973 Program) and the Nature Science Foundation of China. He has got over 130 papers been published in the peer-reviewed English journals, such as Lancet Oncol, Gut, Hepatology, Cancer Res, Oncogene, Clin Cancer Res, Ann Oncol and others.

    Email
    Phone
    Research Interest(s)

    Basic and translational studies on cancer metastasis and anticancer drugs.

    For information on Professor Xie's laboratory, click here and select: Genetic mechanisms and/or prediction biomarkers of cancer metastasis.

     

    Education

    Sept. 1986-July 1991 Bachelor Degree of Medicine, Central South University, Changshai, China

    Sept. 1993-July19 96 Master Degree of Medicine, Sun Yat-Sen University, Guangzhou, China

    Sept.20 00-July20 04 Ph.D., Clinical Oncology, The University of Hongkong, Hongkong, China

    Publications

    1. Zhang JX, Song W, Chen ZH, Wei JH, Liao YJ, Lei J, Hu M, Chen GZ, Liao B, Lu J, Zhao HW, Chen W, He YL, Wang HY, Xie D* , Luo JH*. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis. Lancet Oncol. 2013 ;14(13):1295-306. 

    2. Qian D, Zhang B, He LR, Cai MY, Mai SJ, Liao YJ, Liu YH, Lin MC, Bian XW, Zeng YX, Huang JJ, Kung HF, Xie D*. The Telomere/Telomerase Binding Factor PinX1 is a New Target to Improve the Radiotherapy Effect of Esophageal Squamous Cell Carcinomas. J Pathol. 2013 ;229(5):765-74.

    3. Xu C, Xie D (co-first author), Yu S, Yang X, He, Yang J, Ping Y, Wang B, Yang L, Xu S, Cui W, Wang Q, Fu W, Liu Q, Qian C, Cui Y, Rich JN, Kung HF, Zhang X*, Bian XW*. A novel complex of β-catenin/POU5F1/SOX2 is responsive and dependent on IGF-1R signaling for prediction of poor prognosis in lung adenocarcinoma. Cancer Res. 2013;73(10):3181-9.

    4. Zhu W, Cai MY, Tong ZT, Dong SS, Mai SJ, Liao YJ, Bian XW, Lin MC, Kung HF, Zeng YX, Guan XY, Xie D*. Overexpression of EIF5A2 promotes colorectal carcinoma cell aggressiveness by upregulating MTA1 through c-myc to induce epithelial-mesenchymal transition. Gut. 2012;61(4):562-75.

    5. Zheng F, Liao YJ, Cai MY, Liu YH, Liu TH, Chen SP, Bian XW, Guan XY, Lin MC, Zeng YX, Kung HF, Xie D*. The putative tumor suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2. Gut. 2012;61(2):278-89.

    6. Tong ZT, Cai MY, Wang XG, Kong LL, Mai SJ, Liu YH, Zhang HB, Liao YJ, Zheng F, Zhu W, Liu TH, Bian XW, Guan XY, Lin MC, Zeng MS, Zeng YX, Kung HF, Xie D*. EZH2 supports nasopharyngeal carcinoma cell aggressiveness by forming a co-repressor complex with HDAC1/HDAC2 and Snail to inhibit E-cadherin. Oncogene. 2012;31(5):583-94.

    7. Zhang B, Qian D, Ma HH, Jin R, Yang PX, Cai MY, Liu YH, Liao YJ, Deng HX, Mai SH, Zhang H, Zeng YX, Lin MC, Kung HF*, Xie D*, Huang JJ*. Anthyracyclines disrupt telomere maintenance by telomerase through inducing PinX1 ubiquitinization and degradation. Oncogene. 2012;31(1):1-12.

    8. Cai MY, Tong ZT, Zheng F, Liao YJ, Wang Y, Rao HL, Chen YC, Wu QL, Liu YH, Guan XY, Lin MC, Zeng YX, Kung HF, Xie D*. EZH2 protein: a promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies. Gut. 2011;60(7):967-76.

    9. He LR, Zhao HY, Li BK, Zhang LJ, Liu MZ, Kung HF, Guan XY, Bian XW, Zeng YX, Xie D*. Overexpression of AIB1 negatively affects survival of surgically resected non-small-cell lung cancer patients. Ann Oncol. 2010;21(8):1675-81. 

    10. Rao ZY, Cai MY, Yang GF, He LR, Mai SJ, Hua WF, Liao YJ, Deng HX, Chen YC, Guan XY, Zeng YX, Kung HF, Xie D*. EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-{beta}1 and is a predictor of outcome in ovarian carcinoma patients. Carcinogenesis. 2010;31(9):1576-83.

    Wu Qiuliang
    Title Professor
    Profile

    Research Interest and Specialty
    Prof. Wu participated in class for senior pathologist at national level, graduate courses and the Summer School for Chinese pathologist held by Chinese University of Hong Kong. His current titles are chief physician, professor, advisor of master’s degree student, member of the professional committee of pathology within Chinese Anti-Cancer Association, member of Guangdong Professional Committee of Colorectal Cancer and Nerve Tumors, editorial board member of Cancer Prevention News, Guangdong Medical Journal and Journal of Oncology. Since graduated from college, he has been mainly engaged in teaching and research of clinical pathology and medical diagnosis, thus obtaining rich experiences and some achievements.

    Experience in Diagnosis
    Engaged in clinical pathology and cytology diagnosis for years, accumulating rich experience; a pathology expert in tele-consultation.

    Research
    He had participated in a number of national, provincial and collage research projects, including the eighth five-year key research projects, ninth five-year key research projects, key national projects, key projects of provincial Science and Technology Commission and Health Department, as well as "211 Project" of Zhongshan Medical University; published 22 papers on journals at home and abroad ; received one third prize by provincial Health Department of Science and Technology and one Medical Achievement Award (third prize) by Zhongshan Medical University; drafted NPC histopathology in Tumor Diagnosis and Treatment Norms, and tumors of female reproductive system in Selection of Difficult Cases; Worked with Chinese University of Hong Kong, Karolinska University in Stockholm, Sweden and some US research institutions.

    Teaching
    He had taught courses in vocational middle school and junior college, undergraduate courses in university, participated in the preparation of lecture notes and practice guidance of Pathology; taught courses for graduate students, trained 3 graduate student ; also participated in the teaching courses of pathology for visiting students (five persons a year).

    Email wuql@sysucc.org.cn
    Phone
    Research Interest(s)
    Education
    Publications

    A proposal Concerning the histological typing of Primary nasopharyngeal Carcinoma. Chinese Journal Cancer Research 2001, 13(3):190-197.

    Mu-Yan Cai
    Title Associate Professor and Deputy Director
    Profile
    Dr. Cai received his MD from Sun Yat-sen University. He completed his postgraduate training in pathology at Sun Yat-sen University Cancer Center and postdoctoral fellowship at Dana-Farber Cancer Institute, Harvard Medical School. He is currently an associated professor in the Department of Pathology at Sun Yat-Sen University (SYSU) Cancer Center, Guangzhou, China. He has extensive experience and expertise in the pathological diagnosis of gastrointestinal oncology and lymphoma. His research interest is studying the mechanism of DNA repair deficiency in tumor targeted-therapy and identifying the novel biomarker for tumor pathological diagnosis. He is the recipient of Outstanding Young Talents of Sun Yat-sen University Cancer Center, Guangdong Outstanding Young Medical Talents and Guangdong Natural Science Funds for Distinguished Young Scholar.  He has also received various grants from the National Key R&D Program of China, National Natural Science Foundation of Science and provincial level government, and has participated in several international and national cooperation projects. Dr. Cai has published more than 50 papers in some celebrated journal such as GUT, IEEE Trans Cybern, Protein & Cell, Cell Rep, Oncogene, Ebiomedicine, etc.
    Email caimy@sysucc.org.cn
    Phone +86-20-87342775
    Research Interest(s)
    The pathological diagnosis of lymphoma and gastrointestinal cancers; DNA damage and repair in tumor targeted-therapy
    Education
    M.D. Sun Yat-sen University, China, 2000-2005

    Master Degree in Pathology, Sun Yat-sen University, China, 2008-2010.
     
    Ph.D in Oncology, Sun Yat-sen University, China, 2012-014.
    Publications
    Selected publications
    1. Cai MY, Dunn CE, Chen W, Kochupurakkal BS, Nguyen H, Moreau LA, Shapiro GI, Parmar K, Kozono D, D'Andrea AD*. Cooperation of the ATM and Fanconi Anemia/BRCA Pathways in double-strand break end resection. Cell Rep. 2020;30(7):2402-2415.e5.

    2. Wang X, Chen H*, Gan C, Lin H, Dou Q, Tsougenis E, Huang Q, Cai M*, Heng PA. Weakly Supervised Deep Learning for Whole Slide Lung Cancer Image Analysis. IEEE Trans Cybern. 2020;50(9):3950-3962. 

    3. Zhang C§, Wei S§, Sun WP§, Teng K, Dai MM, Wang FW, Chen JW, Ling H, Ma XD, Feng ZH, Duan JL, Cai MY*, Xie D*. Super-enhancer-driven AJUBA is activated by TCF4 and involved in epithelial-mesenchymal transition in the progression of Hepatocellular Carcinoma. Theranostics. 2020;10(20):9066-9082.

    4. Wei S§, Dai M§, Zhang C§, Teng K, Wang F, Li H, Sun W, Feng Z, Kang T, Guan X, Xu R, Cai M*, Xie D*. KIF2C: a novel link between Wnt/β-catenin and mTORC1 signaling in the pathogenesis of hepatocellular carcinoma. Protein Cell. 2020 Aug 3. (Online ahead of print)

    5. Cai MY§, Tong ZT, Zheng F, Liao YJ, Wang Y, Rao HL, Chen YC, Wu QL, Liu YH, Guan XY, Lin MC, Zeng YX, Kung HF, Xie D. EZH2 Protein: a Promising Immunomarker Useful for the Detection of Hepatocellular Carcinoma in Liver Needle Biopsies. Gut. 2011; 60(7):967-976. 

    6. Zhang YJ§, Chen JW§, He XS§, Zhang HZ, Ling YH, Wen JH, Deng WH, Li P, Yun JP, Xie D, Cai MY*. SATB2 is a Promising Biomarker for Identifying a Colorectal Origin for Liver Metastatic Adenocarcinomas. EBioMedicine. 2018;28:62-69.

    7. Zhu W§, Cai MY§,Tong ZT§, Dong SS, Mai SJ, Liao YJ, Bian XW, Lin MC, Kung HF, Zeng YX, Guan XY, Xie D. Overexpression of EIF5A2 promotes colorectal carcinoma cell aggressiveness by upregulating MTA1 through C-myc to induce epithelial-mesenchymaltransition. Gut. 2012; 61(4):562-575. 

    8.  Zheng F§, Liao YJ§, Cai MY§, Liu YH, Liu TH, Chen SP, Bian XW, Guan XY, Lin MC, Zeng YX, Kung HF, Xie D. The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2. Gut. 2012; 61(2):278-289. 

    9. Tong ZT§, Cai MY§,Wang XG, Kong LL, Mai SJ, Liu YH, Zhang HB, Liao YJ, Zheng F, Zhu W, Liu TH, Bian XW, Guan XY, Lin MC, Zeng MS, Zeng YX, Kung HF, Xie D. EZH2 supports nasopharyngeal carcinoma cell aggressiveness by forming a co-repressor complex with HDAC1/HDAC2 and Snail to inhibit E-cadherin. Oncogene. 2012; 31(5):583-594. 

    10. Cai MY§, Hou JH§, Rao HL§, Luo RZ, Li M, Pei XQ, Lin MC, Guan XY, Kung HF, Zeng YX, Xie D. High expression of H3K27me3 in human hepatocellular carcinomas correlates closely with vascular invasion and predicts worse prognosis in patients. Mol Med. 2011; 17(1-2):12-20. 

    Updated September 2020
    Huilan Rao
    Title Associate Professor
    Profile

    Dr. Huilan Rao is the associate professor of Department of Pathology of Sun Yat-sen University Cancer Center. Dr. Rao obtained her Bachelor in Medicine (equivalent to MD in the US) at Huazhong University of Medical Sciences and Master at Sun Yat-sen University of Medical Sciences, P. R. China in 1990 and 1996, respectively. Her extended practical experience with rountie pathological diagnostic techniques includes pathological slides,histochemical and immunohistochemical techniques. She has been working in pathological diagnosis field for 18 years, major in lymphoma and soft tissue tumor diagnosis. She has served as member of clinical multiple department discussion for difficult lymphoma cases at Cancer Center of Sun Yat-sen University. She is appointed as member of Guangdong Province Committee of Anti-cancer Association with Lymphoma. Also she is a member of Guangdong Pathological Cooperative Group of Lymphoma. 

    Her postdoctoral training at University of Arizona and observer experience at MD. Anderson Cancer Center in USA provided her with great opportunities to explore the fields of tumorigenesis, EBV-associated lymphoma tumorigenesis, peripheral T/NK lymphoma classification. Dr.Rao has published more than 50 research papers. She obtained her supervisor of postgraduate at Cancer Center of Sun Yat-sen University in 2013.

    Email raohl@sysucc.org.cn
    Phone 01186-20-87342712
    Research Interest(s) Lymphoma, soft tissue tumors.
    Education

    Bachelor of Medicine: Clinic Medicine, Huazhong University of Medical Sciences (Tongji Medical University), Wuhan, Hubei, China, 1985-1990

    Master of Medicine: Pathology, Sun Yat-sen University of Medical Sciences, Guangzhou, Guangdong, China, 1993-1996.

    Exchange graduate student: Division of Oral Pathology , Niigata Universtiy, Japan, 1995.

    Research Associate: Department of Biochemistry & Molecular Biophysics, University of Arizona, USA, 2003-2005.

    Fellowship: Department of Pathology, Jiangshu Provincial Hospital , 2011.

    Observer: Department of hematopathology, MD.Anderson Cancer Center, USA, 2012.

    Publications

    1.Yangfen F,Huilan R(corresponding author). 2014. Latest WHO classification analysis of mature T-cell and NK-cell lymphoma and CD30 expression. Chin.J.Pathology, Aug.

    2.HuiLan R,Chen JW,Li M.2012. Increased intratumoral neutrophil in colorectal carcinomas correlates closely with malignant phenotype and predicts patients' adverse prognosis.PloS One, 2012;7(1):e30806.

    3. Cai My,Hou JH,Huilan R(corresponding autor),et al.2011.High expression of H3K27me3 in human hepatocellular carcinomas correlates closely with vascular and predicts worse prognosis in patients. Mol Med .17(1-2):12-20. 

    4.Muyan C,Huilan R(corresponding autor),et al. 2010.Angiomyolipoma histopathological subtypes and clinical features. Chin.J.Exp.Surg.9:1249-1250

    5.Yangfen F,Huilan R(corresponding author),Qiuliang W,et al. 2009.Clinicopathological and Immunohistochemical Analysis of Solid-pseudopapillary Neoplasm of Pancreas. Journal of Sun YAT-SEN University (Medical Sciences).30(2):200-204.

    6. Huilan R,Jinghui Hou, Yili Huang,et al.2001. Clinical pathological characteristics of malignant lymphoepithelial lesion of the salivary glands and its relationship with EV virus. Chin.J.Cancer. 20(3):270-273.

    7.Huilan R,Yili Huang,Jinghui Hou,et al.1999. The significance of detection of EB virus and its products in anaplastic large cell lymphoma. Chin.J.Cancer. 18(4):407-409. 

    8. Liao H, Huilan R,et al. 2010.Retrospective study of clinicopathological characteristics in bronchopulmonary carcionoid. Chin.J.Lung Cancer.13(6):591-597.

    9. Yuhong L,Huilan R,Zhongzhen Guang,et al. 2000.Anaplastic large-cell lymphoma-review and 20 cases report. Chin.J.Cancer.19(9):914-917.

    10.Huangxing L,Huilan R,et al.1998. BLEL of salivary gland-a clinical and pathological analysis of 15 cases.Chin.J.Cancer.17(2):126-128.

    11..Hanliang L,Huilaln R,Jinhui H,et al. 1998.Clinical pathological characteristics of anaplastic large cell lymphoma and the expression of LMP1.Natl.Med.J.China.78(2):150-151..

    12.Hanliang ,Huilan R,Saku,et al. 1997.The significance of detecting EB virus and its products in benign and malignant lymphoepithelial lesions and the salivary glands.Chin.J.Pathol,26(4):225-228.

    13.Huangxing L,Huilan R,et al. 1997.The significance of actinotheraphy in the treatment of Midulicz disease. Chin.J.Modern Med. 7(8):12-14.

    Yun Cao
    Title Associate Professor
    Profile

    Dr. Cao is an associate professor from the Department of Pathology of Sun Yat-sen University Cancer Center. Dr. Cao obtained his Bachelor in Medicine (equivalent to MD in the US) and PhD at Gannan Medical College and Sun Yat-sen University, P. R. China in 1998 and 2012, respectively. After working as a general pathologist for 10 years, Dr. Cao now is focus in the field of genitourinary pathology. Besides the pathological diagnosis, Dr. Cao is also interested in the research of genitourinary tumors, especially the tumor associated fiibroblasts and tumor related Inflammatory cells. 

    Between 2009 and 2011, Dr. Cao was trained in the Laboratory of Cancer Genetics, Van Andel Research Institute, Grand Rapids, MI for 6 months and in the National Cancer Centre Singapore for 11 months as an exchange scholar. Dr. Cao has published 17 research papers.

    Email caoyun@sysucc.org.cn
    Phone Phone: +86-20-87342261 Fax: +86-20-87343807
    Research Interest(s)
    Genitourinary tumors, especially the tumor associated firbroblasts and tumor related Inflammatory cells.
    Education

    2008.09-2012.12 Ph.D., Sun Yat-sen University, Guangzhou, P.R. China

    2001.09-2004.06 Master in Oncology, Sun Yat-sen University, Guangzhou, P.R. China

    1993.09-1998.06 M.D., Gannan Medical College, Ganzhou, P.R. China

    Publications

    1) Li XH, He F, Yan SM, Li Y, Cao Y, Huang CY, Zhou ZW. Increased expression of stomatin-like protein 2 (STOML2) predicts decreased survival in gastric adenocarcinoma: a retrospective study. Med Oncol. 2014 Jan;31(1):763. 

    2) Tang LQ, Chen QY, Fan W, Liu H, Zhang L, Guo L, Luo DH, Huang PY, Zhang X, Lin XP, Mo YX, Liu LZ, Mo HY, Li J, Zou RH, Cao Y, Xiang YQ, Qiu F, Sun R, Chen MY, Hua YJ, Lv X, Wang L, Zhao C, Guo X, Cao KJ, Qian CN, Zeng MS, Mai HQ. Prospective study of tailoring whole-body dual-modality [18F]fluorodeoxyglucose positron emission tomography/computed tomography with plasma Epstein-Barr virus DNA for detecting distant metastasis in endemic nasopharyngeal carcinoma at initial staging. J Clin Oncol. 2013 Aug 10;31(23):2861-9. 

    3) Fu J, Qiu H, Cai M, Pan Y, Cao Y, Liu L, Yun J, Zhang CZ. Low cyclin F expression in hepatocellular carcinoma associates with poor differentiation and unfavorable prognosis. Cancer Sci. 2013 Apr;104(4):508-15.

    4) Cao Y, Zhang ZL, Zhou M, Elson P, Rini B, Aydin H, Feenstra K, Tan MH, Berghuis B, Tabbey R, Resau JH, Zhou FJ, Teh BT, Qian CN. Pericyte coverage of differentiated vessels inside tumor vasculature is an independent unfavorable prognostic factor for patients with clear cell renal cell carcinoma. Cancer. 2013 Jan 15;119(2):313-24. 

    5) Zhang CZ, Pan Y, Cao Y, Lai PB, Liu L, Chen GG, Yun J. Histone deacetylase inhibitors facilitate dihydroartemisinin-induced apoptosis in liver cancer in vitro and in vivo. PLoS One. 2012;7(6):e39870.

    6) Cai MY, Luo RZ, Li YH, Dong P, Zhang ZL, Zhou FJ, Chen JW, Yun JP, Zhang CZ*, Cao Y*. High-expression of ZBP-89 correlates with distal metastasis and poor prognosis of patients in clear cell renal cell carcinoma: ZBP-89 expression in CCRCC. Biochem Biophys Res Commun. 2012 Oct 5;426(4):636-42. 

    7) Zhang CZ, Cao Y, Yun JP, Chen GG, Lai PB. Increased expression of ZBP-89 and its prognostic significance in hepatocellular carcinoma. Histopathology. 2012 Jun;60(7):1114-24.

    8) Ong CK, Subimerb C, Pairojkul C, Wongkham S, Cutcutache I, Yu W, McPherson JR, Allen GE, Ng CC, Wong BH, Myint SS, Rajasegaran V, Heng HL, Gan A, Zang ZJ, Wu Y, Wu J, Lee MH, Huang D, Ong P, Chan-on W, Cao Y, Qian CN, Lim KH, Ooi A, Dykema K, Furge K, Kukongviriyapan V, Sripa B, Wongkham C, Yongvanit P, Futreal PA, Bhudhisawasdi V, Rozen S, Tan P, Teh BT. Exome sequencing of liver fluke-associated cholangiocarcinoma. Nat Genet. 2012 May 6;44(6):690-3.

    9) Cao Y, Xiao-Ping Miao, Yi-Xin Zeng, Dong-Xin Lin, and Jian-Yong Shao. Association between genetic polymorphisms of CYP2A13, CYP2A6 and risk of nasopharyngeal carcinoma in southern Chinese population. Cancer Biology 2011; 1(1): 1-7

    10) Shao JY, Cao Y, Miao XP, Huang MY, Deng L, Hao JJ, Liang XM, Hu LF, Ernberg I, Lin DX, Zeng YX. A single nucleotide polymorphism in the matrix metalloproteinase 2 promoter is closely associated with high risk of nasopharyngeal carcinoma in Cantonese from southern China. Chin J Cancer. 2011 Sep;30(9):620-6.

    11) Li XJ, Ong CK, Cao Y, Xiang YQ, Shao JY, Ooi A, Peng LX, Lu WH, Zhang Z, Petillo D, Qin L, Bao YN, Zheng FJ, Chia CS, Iyer NG, Kang TB, Zeng YX, Soo KC, Trent JM, Teh BT, Qian CN. Serglycin is a theranostic target in nasopharyngeal carcinoma that promotes metastasis. Cancer Res. 2011 Apr 15;71(8):3162-72.

    12) Zhang WD, Chen JY, Cao Y, Liu QY, Luo RG. Computed tomography and magnetic resonance imaging findings of slitary fibrous tumors in the pelvis: Correlation with histopathological findings. Eur J Radiol. 2011 Apr;78(1):65-70.

    13) Zhang WD, Li CX, Liu QY, Hu YY, Cao Y, Huang JH. CT, MRI, and FDG-PET/CT imaging findings of abdominopelvic desmoplastic small round cell tumors: Correlation with histopathologic findings. Eu J Radiol. 2011 Nov; 80(2):269-73.

    14) Li M, Luo RZ, Chen JW, Cao Y, Lu JB, He JH, Wu QL, Cai MY. High expression of transcriptional coactivator p300 correlates with aggressive features and poor prognosis of hepatocellular carcinoma. J Transl Med. 2011 Jan 5;9:5.

    15) Ding PR, An X, Cao Y, Wu XJ, Li LR, Chen G, Lu ZH, Fang YJ, Wan DS, Pan ZZ. Depth of Tumor Invasion Independently Predicts Lymph Node Metastasis in T2 Rectal Cancer. J Gastrointest Surg. 2011 Jan;15(1):130-6.

    16) Cao Y, Miao XP, Huang MY, Deng L, Liang XM, Lin DX, Zeng YX, Shao JY. Polymorphisms of methylenetetrahydrofolate reductase are associated with a high risk of nasopharyngeal carcinoma in a smoking population from southern China. Mol Carcinog. 2010 Nov;49(11):928-34.

    17) Cao Y, Miao XP, Huang MY, Deng L, Lin DX, Zeng YX, Shao JY. Polymorphisms of death pathway genes FAS and FASL and risk of nasopharyngeal carcinoma. Mol Carcinog. 2010 Nov;49(11):944-50.

    Huang Yu-hua
    Title Associate Professor
    Profile
    Huang Yu-hua, MD/PhD, is currently an associate professor in the Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, China. He specializes in lymphoid pathology. Dr. Huang has been a visiting scholar at the Prince of Wales hospital, the Chinese University of Hong Kong and the University of Nebraska Medical Center (UNMC), USA. He is a committee member of the Lymphoma Group, the Pathology Branch of the Chinese anti-cancer association (CACA) and thr CCPI. He is a recipient of the Outstanding Young Pathologist of the Wu Bing-quan Education Foundation, China. Dr. Huang’s primary research interests include the pathological and transnational research on EBV-associated malignancies, including lymphoma and EBV-associated cholangiocarcinoma. He has published more than 40 peer-reviewed papers, including papers in renowned journals such as the Journal of Hepatology, the American Journal of Surgical Pathology, the International Journal of Cancer, and Histopathology.
    Email huangyh@sysucc.org.cn
    Phone +86-20-87342257
    Research Interest(s)
    Lymphoid pathology; pathological and translational studies on EBV-associated cholangiocarcinoma.
    Education
    B.D., Sun Yat-sen University, China, 2001-2006.

    M.D. in Oncology, Sun Yat-sen University, China, 2006-2009.

    Ph.D in Oncology, Sun Yat-sen University, China, 2017-2020.

    Publications
    Selected publications
    1. Huang YH#, Zhang Chris ZY#, Huang QS#, Yeong J,Wang F, Yang X, He YF, Zhang XL,Zhang H,Chen SL, Zheng YL, Deng R, Lin CS, Yang MM, Li Y, Jiang C, Lee T KW, Ma S, Zeng MS, Yun JP*. Clinicopathologic features, tumor immune microenvironment and genomic landscape of Epstein-Barr virus-associated intrahepatic cholangiocarcinoma, Journal of Hepatology, 2021 (74): 838-849.

    2. Huang YH, Shi XL, Zhong P, Wang Y, Xiao HL, Zhou XG, Yun JP: De Novo Testicular Extranodal NK/T-Cell Lymphoma: A Clinicopathologic Study of 21 Cases With Review of Additional 18 Cases in the Literature. Am J Surg Pathol 2019, 43(4):549-558.

    3. Zhang JJ, Luo XY,Huang QT, Huang YH*.Clinicopathological and prognostic features of nasopharyngeal carcinoma in children and adolescents: A retrospective study of 196 cases in South China, International Journal of Cancer, 2021, 148(5): 1087-1096.

    4. Miao LF, Guo N, Feng YF, Rao HL, Wang F, Huang QT, Huang YH*. High Incidence of MYC Rearrangement in HIV-Positive Plasmablastic Lymphoma. Histopathology 2020, 76, 201–211.

    5. Huang YH#, Rao HL#, Yan SM, Wang F, Wu QN, Feng YF, Zhang YJ*. Serum EBV EA-IgA and VCA-IgA antibodies can be used for risk group stratification and prognostic prediction in extranodal NK/T cell lymphoma: 24-year experience at a single institution. Ann Hematol 2017, 96(8):1331-1342. 

    6. Chen SL#, Huang QS#, Huang YH#,Yang X, Yang MM, He YF,Yun C, Guan XY,Yun JP*. GYS1 induces glycogen accumulation and promotes tumor progression via the NF-kappa B pathway in Clear Cell Renal Carcinoma, Theranostics, 2020, 10(20): 9186-9199. 

    7. Tao LL#, Huang YH#, Chen YL, Yu GY, Yin WH: SSTR2a Is a Useful Diagnostic Marker for Follicular Dendritic Cells and Their Related Tumors. Am J Surg Pathol 2019, 43(3):374-381. 

    8. Huang YH, Luo MH, Ni YB, Tsang JY, Chan SK, Lui PC, Yu AM, Tan PH, Tse GM: Increased SOX2 expression in less differentiated breast carcinomas and their lymph node metastases. Histopathology 2014, 64(4):494-503.

    9. Huang YH, Yan SM, Liu LL, Lu JB, Yang X, He YF, Yun JP. Incidental lymphoma in lymph node dissection for carcinoma in the abdominopelvic cavity: a single-institution experience. Virchows Arch 2019, 475(3):365-372.

    10. Huang YH, Chen SL,  Wei R,  Guo XJ, Yang X,  Cao QC, Yang Y,  Yun JP. CD20-positive Extranodal NK/T-cell Lymphoma: Clinicopathologic and Prognostic Features. Virchows Arch.2020.477(6):873-883

    Updated March 2021

Where are we | Contact us|

Copyright:Sun Yat-sen University Cancer Center Designed by Wanhu.